Eli Lilly and Company
CHRONIC NIGHTLY DOSING OF LASMIDITAN FOR MIGRAINE PREVENTION
Last updated:
Abstract:
The present invention relates to chronic nightly use of lasmiditan for the prevention of migraine, particularly therapy resistant migraine which is defined herein as migraine refractory to two or more prior monotherapy and/or dual therapy treatment or prevention regimens.
Status:
Application
Type:
Utility
Filling date:
3 Sep 2019
Issue date:
4 Nov 2021